Search research articles
Contact Us
Filters
Showing results (151-160 of 277) with videos related to
Page
of 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
David Hong, Jeffrey Infante, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Molecular Cancer Therapeutics
|
September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents
Prasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Cancer
|
July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials
Goldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2020
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku, Albiruni R Abdul Razak, Ping Chi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]
Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Oncotarget
|
December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomes
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
Jennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials
Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Page
of 28
Search research articles
Search
Showing results (151-160 of 277) with videos related to
Sort By:
Page
of 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
David Hong, Jeffrey Infante, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Molecular Cancer Therapeutics
|
September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents
Prasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Cancer
|
July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials
Goldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2020
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku, Albiruni R Abdul Razak, Ping Chi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]
Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Oncotarget
|
December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomes
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
Jennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials
Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Page
of 28